MADRID, 5 (EUROPA PRESS)
Ratiopharm has made available to health professionals the acid generic ibandrónico for the treatment of osteoporosis in postmenopausal women at high risk of fracture, as tablets coated 150 milligrams once per month.
The company stands out that pharmacological presentation in one shot per month “facilitates thus adherence to treatment”, that he has shown in studies of authorization, the same effectiveness to the daily dose of 2.5 mg.
Tablets are film-coated. The tablet should preferably take the same day of every month, always after the night fasting (such as at least 6 hours) and 1 hour before the first meal or drink of the day (or any other medication or supplement by mouth, including calcium).
All osteoporosis treatment goal is to reduce the risk of fracture. Bisphosphonates are recommended as first-line treatment of this disease drugs and, at present, are the drugs most commonly used in the treatment of osteoporosis, because anti-fracture efficacy has been amply demonstrated and, in general, are well tolerated.
Acid ibandrónico is a very powerful bisphosphonate that belongs to the Group of nitrogenous bisphosphonates. The drug, which has shown a reduction in the risk of vertebral fractures, leads to a progressive net increase in bone mass and reduces the incidence of fractures in postmenopausal women until the values prior to menopause.
